Tenders Are Invited For Pharmaceutical Products – Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V For Pharmaceuticals (Open House Procedure)

Pharmaceutical Products – Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V For Pharmaceuticals (Open House Procedure). The Procurement Requirement Includes All Medicinal Products With The Active Ingredients Named In Appendix 3 To The Conditions Of Participation (So-Called List Of Active Ingredients And Deadlines). Contracts Can Be Concluded For Individual Active Ingredients. The Procurement Requirements Were Not Divided Into Lots. This Is An Open House Procedure. To The Extent That Wording Is Used In This Announcement That Indicates The Division Of Procurement Requirements Into One Or More Lots, This Is Solely Due To The Specifications Of This Announcement Form. In This Context, Reference Is Made To The Non-Applicability Of Procurement Regulations Described At The Beginning Of Section 2.1. The Aok Starts The Open House Process With The Following Active Ingredients (So-Called Starting Active Ingredients): Serial No. 1 Of Appendix 3 To The Conditions Of Participation: Adalimumab; Serial No. 2: Beclometasone Dipropionate + Formoterol Hemifumarat-1 Water In The Dosage Forms Inhalation Powder, With The Potencies 100/6 Μg And 200/6 Μg, As Well As Metered Dose Aerosol/Inhalant With The Potency 200/6 Μg; Serial No. 3: Betamethasone Valerate + Fusidic Acid 0.5 Water; Serial No. 4: Dimethyl Fumarate; Serial No. 5: Etanercept; Serial No. 6: Filgrastim; Serial No. 7: Follitropin Alfa; Serial No. 8: Infliximab; Serial No. 9: Lanthanum(Iii) Ion; Serial No. 10: Latanoprost + Timolol Hydrogenmaleate; Serial No. 11: Leuprorelin Acetate; Serial No. 12: Lipegfilgrastim; Serial No. 13: Mesalazine In The Strengths 500 Mg, 1000 Mg, 1200 Mg, 1500 Mg, 2000 Mg, 3000 Mg, 4000 Mg; Serial No. 14: Naproxen; Serial No. 15: Natalizumab; Serial No. 16: Octreotide (Depot); Serial No. 17: Omalizumab; Serial No. 18: Oxycodone Hydrochloride + Naloxone Hydrochloride-2-Water; Serial No. 19: Pegfilgrastim; Serial No. 20: Raltegravir; Serial No. 21: Ranibizumab; Serial No. 22: Rasagiline; Serial No. 23: Rotigotine; Serial No. 24: Ticagrelor; Serial No. 25: Tocilizumab; Serial No. 26: Ustekinumab. The Aok Reserves The Right To Adjust The Procurement Requirements Of This Open House Procedure In The Course Of The Further Procedure By Supplementing Appendix 3 With Additional Active Ingredients Or Reducing Individual Active Ingredients From Appendix 3. In The Event Of An Expansion Of Procurement Requirements, Discount Agreements For Medicinal Products With These Additional Active Ingredients Would Also Become The Subject Of The Present Open House Procedure. Of Course, This Would Not Expand The Content Of Contracts Already Concluded For Other Active Ingredients, But Rather A New Contract Would Have To Be Concluded (See Also Sections A.I.1 And A.Iii.4 Of The Conditions Of Participation). If The Client Wishes To Terminate All Discount Agreements For An Active Ingredient From Annex 3, It Can Declare This To All Discount Contract Partners For This Active Ingredient At The Same Termination Time And Cancel The Open House Procedure For The Same Active Ingredient. In This Case, The Aok Will Immediately Announce The Cancellation Of This Open House Procedure For The Same Active Ingredient In The Supplement To The Official Journal Of The European Union